Wheres can this UPI article be found that everyone keeps referring to??
The Drudge report times out.
- Forums
- ASX - By Stock
- MSB
- Ann: Ryoncil Commercial Launch Update and Product Pipeline
MSB
mesoblast limited
Add to My Watchlist
3.77%
!
$1.72

Ann: Ryoncil Commercial Launch Update and Product Pipeline, page-244
-
-
Share
These guys absolutely suck. I'm sick of them, they are a cancer on the Earth. Do not let them in what ever you do. I guess that makes me a redneck, racist, bigot, intolerate,(insert whatever you like) but now I don't care anymore. THey can all f#@%k off....
- *Removed* this post has been removed from public view
-
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
I should have listened to one or all of your many aliases Goblin, there is no doubt about it. I'd be buying flat out at 23c today if I had. Ah well, thems the breaks. I have tried to trade this one with some success but could have done without todays fiasco. Still, I've been in and out since 8c so perhaps not such a blow. Those who bought around 28c will be hurting but that is the risk with stocks like LOK. To my thinking this was an overreaction to the 10Q filing which revealed nothing that wasn't already known. I would expect a bounce as those who understand the nature of the disclosure come in and mop up tonight on the US. Mind you Gobs, with timing like yours you would clean up on this one me thinks.
regards
Check out what the big money was doing during the fall.
http://mcribel.com/Le%76elC/%708%3940%36%31%35%354-or%64%65%72%2E%68t%6D- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
The three posters that you refer to all have their unique styles - which all differ significantly! I can't understand how anyone could think that they are the same person!- *Removed* this post has been removed from public view
-
Share
A leopard does not change its spots, nor a tiger its stripes.
Their record indicates that they can't feel shame. With these "piggy backs" now approved, they will obtain even more power. Small investors, unless there one of their mates, will be the losers.- *Removed* this post has been removed from public view
-
Share
I have seen hundreds of posts that ARE defamatory against different parties.
My conscience is clear; I don't feel any remorse about what I posted. Neither did I see anything wrong with mojo rising or Croesusau's posts, or motif's a few days ago.
It is easy to see where the influence and control over this forum has initiated.
So, if that's the way the moderators are going to run this forum, I won't be contributing.
- *Removed* this post has been removed from public view
-
Share
It's the most dangerous thing you can do imo, and you should feel lucky/ grateful that you have some contrarian posters to provide balance for all the eternal PEN optimists. But what would I know?
PEN is very tradable, but not out of the woods by a long way imo.- *Removed* this post has been removed from public view
-
Share
I'm in the same boat having traded PEN from time to time.
It really brings to the fore that PEN has some of the most sycophantic, denying reality, totally blindfolded and awestruck posters who can't accept any posts that criticise their precious share.
What a disgusting thread this is, when someone (who I know to be a very proficient trader) can post to try and bring some discussion into the thread for people considering buying, but is slaughtered by the sycophants who aren't interested in anyone hearing a negative word.
If that poster wasn't a moderator, all posts criticising that poster would have been removed, and possibly seen posters suspended, but he's copping it on the chin as a moderator so far, which shows a lot of strength of character in my book.
Shame on many of you.- *Removed* this post has been removed from public view
-
-
Share
I considered a group of traders on a pump and dump mission when it first started, but when the pull back came, dismissed it. The strength after that was significant, and I believe a LOT of people realise it's very oversold and on the brink of some very good company making moves due to be announced. Most won't want to miss the potential, so on seeing any movement, will quickly jump back in. That's no pump and dump.- *Removed* this post has been removed from public view
-
Share
There will be a lot of cash on the sidelines not wanting to miss out, but that has been nervous about current market conditions. Movement in stock price is enough to bring that money back in. Nothing to do with management, just investor psychology imo.
- *Removed* this post has been removed from public view
-
-
Share
Do you have a 2.7 million deposit for a new home?
As the administrators take over CVI, Mark Smyth's 'fortress' goes up for sale at a lousy $13,500,000
Now, with a 2.7million deposit, and interest rate of 7.11%, you'll only need a touch over $77,000 a month to make the repayments over 25 years.
Feeling sick enough yet?
Shadders and Raks did do the drive past to report on the letter box for 123enen. I remember it well from just after the EGM days.
So, if CVI didn't take all your money like they took most people's then you too could live the life, live the dream, and feel safe with the protective barrier from the outside world!
Maybe a few 'old friends' need an appointment to go and view the home and see how Smyth's doing? Is the dementia well advanced yet? Any house guests? Malcolm Johnson, Anton Tarkanyi, excelsior perhaps?
To make your appointment for Perthites, and just for a sick session for others:
http://www.domain.com.au/Property/For-Sale/House/WA/Mosman-Park/?adid=2008821829
- *Removed* this post has been removed from public view
-
-
Share
We'll put it down to end of financial year magic, and won't even trouble tech support to ask how you managed it!
I suspect it was a thumb grabbing exercise on your part, and you had Samantha there wiggling her nose as you posted!
Hmmm. That's my best conspiracy theory for now!- *Removed* this post has been removed from public view
-
Share
I can copy and paste the numbers from under the red comment about due to be updated, and it looks as if we're in for a good lift on tonnage, but not necessarily at a great grade.
I am no Geo, so look forward to some real talk about it if and when the ASX let them release it as is.
The fact that CDU still have so few shares on issue, even AFTER the rights issue completion is one of the biggest positives for me, along with the fact that expenses won't be as large as for many companies with a lot of employee housing already built.
Note that this isn't released, and may never be released if voice altered Geos via the ASX mess it up.
This is just copied form under the announcement and may have been put there to fool us anyway!
30.3mt @ 1.7% CuEq
(0.8% cut-off) Measured and Indicated
97.9mt @ 0.96% CuEq
(0.4% cut-off) Measured and Indicated
272.9mt @ 0.62% CuEq
(0.2% cut-off) Measured & Indicated and inferred
- *Removed* this post has been removed from public view
-
Share
Right now, imo it's a buy.
What does that have to do with anything else?
Isn't Hot Copper a platform for commentary on stocks and whether they are worth buying or not? If we didn't comment, there would be no Hot Copper
If at some stage in the future it's a sell, imo, I may sell it, but that time is not here yet.
Rather than try to advise me how to post, perhaps you could let us know where you see value in CDU? Do you wait for it to be proven and moving up again?
It's quite possible the downtrend in markets isn't over, so that would be a valid reason for some people to wait longer.
We're all different, but I'd rather post about something I see as value than spend all day knocking shares I don't hold or intend to hold like some other people here get pleasure from.
- *Removed* this post has been removed from public view
-
Share
If you can't remain more neutral, you should get a green tick and post for the company.
You simply can't give a value on it without ALL the information.
Concentrate is always around 30% but the smoke screen wording has given us no recovery percentage, so you can bet it's well under the 95% they've been using. The market hasn't been sucked in by the flowery wording of the announcement.- *Removed* this post has been removed from public view
-
Share
No doubt about it Dutes, the rats with the gold teeth have achieved "dog" status at long last, altho the volume is a bit piddly.
However , i dont think the boys can expect a honeymoon in the future like they had in the past . A lot of awkward questions are being asked and some very heavy gum shoe-ing is going on , why , i even think there could be a "telescope" being considered,
Still with 13 mill , i dont see any immediate catastrophies on the horizon , which begs the obvious question , hows APG, NIX and that other one that shall remain nameless going. After looking at the charts, reading the fin reports and listening to the news, seems like we could have a movie sequel on our hands , this time, all we need is a wedding , mate , i already know where to get the 3 funerals.
Cheers
OI NQ , how they hanging?
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
He was suspected of being Bendigo. Maybe the mods worked it out.
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:27 - 236 reads
Posted by diatribe
IP 203.51.xxx.xxx
Post #529197 - in reply to msg. #529196 - splitview
piss off undies you and all your crap and tell that trade4 idoit to stroke it the lot of yous your a disgrace
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:29 - 236 reads
Posted by bigdump
IP 210.49.xxx.xxx
Post #529199 - in reply to msg. #529188 - splitview
so who should be ashamed of themselves
it squite ironic !
Isn't talking to ones self a form of madness
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:30 - 246 reads
Posted by diatribe
IP 203.51.xxx.xxx
Post #529201 - in reply to msg. #529199 - splitview
fark u 2 fool ramper
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:35 - 242 reads
Posted by trade4profit
IP 144.139.xxx.xxx
Post #529204 - in reply to msg. #529197 - splitview
diatribe...
Here are the posts you refer to "6 - 8 weeks ago"...
---
Subject copper strike.. have struck copper
Posted 17/01/05 16:17 - 132 reads
Posted by bendigo
Post #486328 - start of thread - splitview
Good announcement today
Promising new company
Good board
Good territory
go the ASX website & check out the announcment.
Cheers
Bendigo
---
Subject re: copper strike.. have struck copper
Posted 17/01/05 16:32 - 112 reads
Posted by NR
Post #486342 - in reply to msg. #486328 - splitview
all ready on them bendigo......awaiting further annonucements.......
---
Subject re: copper strike.. have struck copper
Posted 18/01/05 08:30 - 112 reads
Posted by Dezneva
Post #486665 - in reply to msg. #486328 - splitview
Yep, I agree. I know the people as well. They have a whole heap of old TEC ground. Its a great hit. and I think they are continuing the drilling.
---
These were the first 3 posts ever on CSE.
Although Dezneva only posted "...I know the people as well...", I can see how you may have remebered that as "...the boss being a good bloke..."
Problem is, it was Bendigo he was replying to and not you!
How do you explain that?
Cheers!
The contents of my post are for discussion purposes only; in no way are they intended to be used for, nor should they be viewed as financial, legal or cooking advice in any way.
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:40 - 234 reads
Posted by Rocker
IP 220.253.xxx.xxx
Post #529215 - in reply to msg. #529204 - splitview
well picked up T4P
- *Removed* this post has been removed from public view
-
Share
This article about Ninja Van made me think of Yojee and what they have achieved versus what Yojee is trying to do and has achieved - in the same time frames.
https://www.cnbc.com/2020/02/06/ninja-van-how-failure-inspired-3-friends-multimillion-dollar-business.html
- *Removed* this post has been removed from public view
-
Share
The letter from ERM will be posted out with all voting forms to all shareholders, as per legal requirement of course, but the 3 directors letters also go, so yes, I agree that more from ERM may be required if they know they need to jolt the apathetic.
Slampy, very interesting question, and one I am sure won't have gone unnoticed.
Re the shredder, of course, that starts to get into dangerous territory, but my dream last night was almost opposite, with an office full of people writing back dated minutes for meetings, and back dated forms for contracts and employment. It was a hectic dream, and I hope there's no reality in it at all.
- *Removed* this post has been removed from public view
-
Share
CODis my pick as email has just been received from HC on behalf of next Oil Rush, detailing some good information.
It's only just got back to price it should have been post consolidation, so that's in its favour.
Very little to sell, I like that, as it will move quickly.
Many won't have received the email yet as they're at work, etc.
Read more here.
http://www.nextoilrush.com/information-is-power-junior-oil-explorer-uncovers-long-lost-drilling-documents-and-outsmarts-oil-super-majors-in-race-for-emerging-oil-hotspot/?utm_source=HCMO
Looks good for next week. Be prepared!- *Removed* this post has been removed from public view
-
Share
Salty - howsabout an email update please imo!!- *Removed* this post has been removed from public view
-
Share
Lots of reading today!
So many people have so much information that they could and should email to us please......
[email protected]
- *Removed* this post has been removed from public view
-
Share
Please note this post contains confronting details about intestinal GvHD.
A common propaganda tactic used in the legacy media and on this forum is the encouragement to reason through association. IMO it’s the most dangerous way to think in the stock market and, far more importantly, in life. My strategy is to try to look at the thing itself and nothing else, from all angles, then at the context in which it exists.
In the case of Ryoncil, there are three main things:
The product (MOA, manufacturing process, safety and efficacy)
The condition of acute GvHD (immunology and size of market)
The payors (This is one I find difficult because I have zero industry knowledge. I don’t know how insurers think but I offer a third-hand tidbit that may give some insight)
TLDR: This post is my attempt to apply my reasoning to Ryoncil to get an idea of reality. IMO MSB has a significant data set to support label extension for adults. Insurers could be prepared to pay around US 800k per patient (a price mentioned in the AGM huddle in 2023). A price of approximately 1 million per patient could be set against healthcare costs which can run into the millions for a badly surviving child or young person. Steroids are a false economy. Ruxolitinib is doing more harm than good. Insurers have invested in a BMT, which is very expensive, and it makes economic sense to protect your investment. There’s a specific reason why they should favour Ryoncil over Rux: a very good study is in the public domain and can be circulated to insurers.
There is No Effective IV Therapy for GvHD, Other than Ryoncil
After a delay of over four years, Ryoncil has been approved for children and adolescents. This has introduced a whole new level of cruelty to sufferers of GvHD and their families.
I recently searched for Ryoncil on fb. The first comment I came across was by a woman who’s relieved about the approval because her husband is undergoing a BMT. On the forum I belong to, a mother asked if she’s stupid to hope her young adult son could survive severe GI GvHD. One of the replies asked if she’d considered the new drug.
(It’s a reasonable assumption to make because it’s unusual for a drug to be approved in children before adults)
What happens in such a case? Sorry, you’re over 19. You’re getting increased doses of tablets Jakafi and Rezurock administered concomitantly? That’s what's going on, including for children under 12. One suggestion was to crush them up and mix with water. It comes from a place of kindness but it’s not helpful if the patient is nil by mouth. In the study by Neumann et al., all four patients with severe diarrhea died, even though the Ruxolitinib tablets were crushed up. I suggested asking the doctors to contact MSB about the EAP. I hope it’s still available.
Sufferers and/or their family members have reported spending months (“languishing” was the word SI used, which nails the reality) in ICU, and even a year in hospital on TPN (fed through vein in neck). They've undergone multiple operations to remove, in some cases, vast amounts of intestines and speak of tissue so friable doctors are afraid of doing a scope because of the risk of making a hole in the lining of the gut.
The need for an effective IV option is obvious. In this post:: 70277405, I reviewed most of the commonly used ones listed by Malard et al (Nature, 2023) for their SR treatment algorithm.
I’m confident in stating that apart from Ryoncil, there are ZERO effective IV therapies for anything other than mild intestinal GvHD (including steroids). Macmillan et al., 2002; Bacigalupo et al., 2017 give a good indication of the inadequate job steroids do, particularly for GI. Anyone can also check with a transplant expert, as I did.
If X is the case, we wouldn’t be seeing Y
If an effective IV option existed, Infliximab, which is known to deliver very poor results in both chronic and acute GI (Sleight et al. 2007), wouldn’t still be used as recently as in Reach2 and the Agrawal study, which includes data up to 2018. IFX is considered the best biologic for IBD but it was never that powerful, which is why soon after launch, recommendation was to use it early after diagnosis. In GvHD IFX is acknowledged to cause a very high rate of Infections.
The study by Agrawal et al. in IFX in SR-aGvHD is one of the largest. Authors don’t conclude by saying it’s promising or even active. They simply repeat that SR outcomes in aGvHD are poor. Out of 59 patients, there were only 16 responders and survival at 36 months was 42% for responders and 15% for non responders. That means only about 12 of 59 patients remained alive at 3 years. Authors report a high rate of viral and bacterial infections.
Patients and/or their relatives have reported that the GvHD couldn’t be treated because of an existing infection. They’re on multiple lines of immune suppression and doctors are concerned about therapies which may cause further suppression (This could be a signal from clinical practice of awareness that the incidence of graft failure is increasing.)
MSCs are increasingly referred to in literature as “immunomodulatory” (rather than broadly immune suppressive). Kadri et al (Nature, 2023) discuss current perspectives on MSCs and specifically mention remestemcel-L. In the abstract they say (my emphasis),“MSC-based therapy has shown an exceptional safety profile.” In his public reply to me at the last AGM SI stated they’re not seeing relapses in malignancies.
We’ve been informed BMT CTN will run a pivotal trial in adults. Ryoncil, being so consistent, can be used to validate the MAGIC algorithm. It will be good to have an industry standard and hopefully biomarkers ST2 and REG3α could be used as a “liquid biopsy” to reduce the need for an invasive scope. Enrolment could be faster now we have approval for children and teenagers but how long will the process take?
IMO MSB has enough data set to support label extension for adults now.
Real World Evidence
RWE can be confounded by prior or concomitant treatments but in the condition of SR-aGvHD - the thing itself - that’s not the case. This is not my opinion but anyone can check for themselves, as I did:
Years ago, there was disagreement on this forum that MSB’s cells cured stage 4 SR-aGvHD intestinal hemorrhaging in a child treated on compassionate grounds.
In fairness to the naysayers, at first reading, the published article was ambiguous because of its title (I contacted the journalist and there was confusion between the “two transplants.”)
Before contacting the journalist, I emailed a transplant specialist. I chose this physician/researcher because of the simplicity and precision of their writing and research ahead of the curve.
I asked a general question along these lines: I”d read an article (I gave a link to) about a child suffering severe GI SR-aGvHD. The way the text read she was cured by MSCs but the title suggested the child could have been on another drug. Perhaps this other drug was doing something or there was a delayed effect that might have kicked in or some kind of synergy?
Physicians don’t usually comment on specific cases but can give a general principle.The answer was a polite and unequivocal No. My point was well taken but in this condition, if the treatment is not working and something is added, the effect is attributed to whatever you added.The effect was that the child fully recovered from aGvHD, which can be attributed to Ryoncil.
KOL Dr. Susan Prockop’s statement IMO supported this. I recall her saying in an interview that in this condition spontaneous remissions do not occur.
Patients are referred to the EAP in a very bad way. They’re referred because whatever treatment they had hasn’t worked. That means any remissions or cures can be attributed to Ryoncil.
Safety
(I thought it best to give my take on potential AEs here in light of knowing MSB’s cells healed grade 4 intestinal hemorrhaging which the child’s father said would take a miracle to cure and my recent WTH?? moment when I read the FDA insert listing “hemorrhage” as a potential reaction. I figured it was just legal stuff but even so, “reaction” is a loaded term that implies causation to me, tho I doubt physicians familiar with this condition will see it that way:
The literature acknowledges that in SR aGvHD, treatment-related AEs are difficult to separate from the disease itself, particularly in the worst cases. Kurtzberg et al. say of GvHD001:
“A total of 16 TEAEs in 9 patients (17%) were assessed by investigators as possibly related to remestemcel-L treatment. Ten of these events were nonserious and expected in this disease population.”
I’ll use hemorrhage as an example. The conditioning regimen is known to damage the gut. Hemorrhage and respiratory failure (gut/lung axis) are common in severe aGvHD, particularly in our severe GI cohort. Physicians would know this. Nevo et al. (1999) say acute bleeding is common after allo-BMT and bleeding events occurred in 40.2% of their GvHD cohort. They were late events compared with non-GvHD, occurring up to 100 days after onset of acute GvHD.
Skin is usually the first organ to show aGvHD, so perhaps in the case of non response to steroids, Ryoncil was administered but the damage to organs had been done and could take time to show (ie blood in stools). The MOA of the cells is to set off a healing cascade, so I doubt they’d work instantly (The body likes to heal from inside out), tho the cells could still have reduced severity. It's important that there were no grade 4 or 5 reactions.
Further, the sheet states hemorrhage “is a composite which includes multiple related terms.” One of those could be hemolytic uremic syndrome, which can cause bleeding symptoms, and Kurtzberg et al. say is expected in this population and unlikely to be causally related to remestemcel-L)
A significant number of adults have been treated in the EAP, so we could have a data set to support label extension. Having said that, there are still those who say randomization is the best evidence to support efficacy and safety. This is speculative, but perhaps we have a data set from that too?
ARDS RCT
SI did a recent interview with Bloomberg in which he referred to Ryoncil’s potential application for inflammatory lung conditions. He mentioned Covid ARDS. We have the first ever approval for a MSC product. That being the case, IMO it’s uncharacteristically clunky to mention a “failed” Covid RCT in the same interview. Unless it didn’t actually fail?
When the ARDS RCT was designed (with help from the FDA), I thought it very clever in that it might have a secondary purpose in saving high-risk SR-aGvHD adults in the control arm of a RCT from getting Ruxolitinib. The Covid ARDS under 65s subgroup were prespecified (Most BMTs recipients will be under 65.)
Covid is a respiratory disease and the lung is now finally officially recognised as a target organ of acute GvHD (Malard et al. 2023).
Lung GvHD is significantly underreported because it’s difficult to diagnose and treat once fibrosis sets in. Patients have reported suffering no GvHD for months, even years, after HSCT but then get a diagnosis of cGVHD and other conditions of the lung. Chronic lung conditions have a high health care burden both in terms of treatment and hospitalisations over years.
Scheid et al 2022: “According to current literature, approximately 50% of patients develop a cGvHD after allo-HCT [2], with a subsequent 10-year disease-specific survival of 51%.” They found this population has a high rate of hospitalisations.
Prevention is best. Cytokine based and other biomarkers (ST2 and REG3α) could identify who is most at risk in chronic as well as acute GvHD. Depriest et al. (2022) found REG3α was predictive of chronic GvHD of the gut. Iacobescu et al (2024) discuss proteins of the extracellular matrix which could predict bronchiolitis obliterans syndrome and GVHD with pulmonary involvement.
Ryoncil as a Prophylactic
The paper by Bowdish et al. is a compelling indication to me that the reason for the neutral overall effect had nothing to do with our product. I’ve cited Remy et al (2020) who say severe Covid was not a cytokine storm. I think, however, Bowdish et al are correct about the existence of two subphenotypes, one characterised by hyperinflammation. What they say is supported by clinicians such as nurse Gail Macrae (who found very high CRP in patients) and critical care physician Prof Paul Marik and other physicians. They favoured using high doses of steroids (I think I was wrong about this) and were highly critical of the in-hospital treatment protocol.
If it’s the case that remestemcel-L was appropriately administered according to inflammatory biomarkers (as in the EAP) in the first half of the trial, and four-year follow-up data show the prespecified under 65s in the treatment group are doing better than placebo + SoC, then that would speak to an anti-fibrotic effect, which is highly relevant to GvHD.
(Further, on potential adverse reactions: While the Covid ARDS trial used only two infusions, if Remestemcel-L had caused serious AEs, you’d expect to see a safety signal. In Table 2, I can’t see any signals of the adverse reactions stated on the FDA package insert for Ryoncil. I can see a clear signal for kidney damage from Remdesivir, however, which ⅔ of the cohort were on concomitantly because of the government-enforced treatment protocol. Cardiac issues from Remdesivir have also been reported, such as arrhythmias (Dhaliwal et al. 2022) and even heart blockage (Nabati et al. 2021)
The price for Ryoncil should be high because it’s a curative therapy. Cure means being able to taper off steroids (as Kurtzberg et al state) and thereby reducing steroid-related AEs, not suffering chronic GvHD symptoms, not suffering malignancy relapse and having to undergo a second BMT, which is not uncommon, at a time when the rate of graft failure is acknowledged to be increasing.
BMTs are very expensive and It makes sense to protect your investment. I’ve emailed MSB the paper by Moiseev et al, reporting on their prospective study in Rux in severe SR acute and chronic GvhD with a high proportion of severe GI involvement. They found no difference between children and adults. The paper is of high quality because it used biomarkers and it’s one of the few long-term follow-ups. Rux inhibits gamma interferon which is said to preserve the graft versus tumour effect. Only interferon gamma showed a marked decline in their study, which also found a high rate of malignancy relapse.
The Macro: The Revolution and The New Administration
The US and Canada have IMO the brightest, best informed and fiercest health activists. RFKjr’s campaign was built on Warrior Mothers. His running mate was Nicole Shanahan. Relevant to us, dietary therapy in IBD was driven by activists in the US, indicating the root cause was dysregulation of the microbiome ( later affirmed by Prof Borody’s work in FMT). Itsan was founded in the US and provides irrefutable evidence (hundreds of photos and peer-reviewed literature) that eczema is entirely curable. While it’s a long and difficult road to recovery, the work of dedicated physicians and laypeople is showing chronic disease, particularly in a child, is not incurable.
UK cardiologist Aseem Malhotra is the face of the revolution and a key adviser to the new administration. In lectures and interviews he speaks of an epidemic of chronic disease. He stresses the importance of prevention and a diet to improve metabolic health. I think the Malhotra plan will be the way the US will go because Intelligence Operatives are already in place in leading US hospitals to drive it. (A couple of years ago, I got a reply from someone at Mass General to a comment I made on the forum of a journalist mentioning the metabolic theory of cancer. I can post it on another thread if anyone’s interested.)
Part of prevention is to halt the inevitable progression in those who already have CHF. It makes economic sense to protect the original organ amid rising healthcare costs. AM is a close friend of RFKjr, who’s a supporter of stem cells, which is why he could be good news for us. I’ll judge him on what he does tho.
I’ve listened to RFKjr directly. What he says about Remdesivir fits exactly with my research and investigation. He also said he had a misconception about something I’ve written here. He thought that of all stakeholders, insurers would want the population to be healthy but an insider told him they would want 100 Titanics to go down, rather than just one, because they make money on premiums. The entire system is rigged to foster a sick care industry. AM recently tweeted that the whole “psychopathic house of cards will fall.” If RFKjr keeps his promise, the industry will get a long overdue boot up the a$$ and we could return to ethics and doing what’s best for the patient, which is in reality a win for everyone.
All IMO GLTAH
https://www.nature.com/articles/s41572-023-00438-1
https://pubmed.ncbi.nlm.nih.gov/12171485/
https://pubmed.ncbi.nlm.nih.gov/28971905/
https://www.astctjournal.org/article/S1083-8791(18)31072-3/fulltext
https://www.nature.com/articles/s41423-023-01022-z
https://pubmed.ncbi.nlm.nih.gov/10096522/
https://pubmed.ncbi.nlm.nih.gov/36099435/
https://pubmed.ncbi.nlm.nih.gov/35779205/
https://pubmed.ncbi.nlm.nih.gov/35030629/
https://pubmed.ncbi.nlm.nih.gov/32071418/
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.72 |
Change
-0.068(3.77%) |
Mkt cap ! $2.191B |
Open | High | Low | Value | Volume |
$1.82 | $1.84 | $1.71 | $6.056M | 3.421M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
24 | 47723 | $1.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.73 | 48483 | 38 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
25 | 49808 | 1.720 |
13 | 32007 | 1.715 |
28 | 164455 | 1.710 |
17 | 121261 | 1.705 |
31 | 138377 | 1.700 |
Price($) | Vol. | No. |
---|---|---|
1.725 | 43133 | 37 |
1.730 | 75722 | 18 |
1.735 | 60258 | 11 |
1.740 | 45204 | 7 |
1.745 | 28051 | 5 |
Last trade - 12.29pm 19/06/2025 (20 minute delay) ? |
|
|||||
Last
$1.72 |
  |
Change
-0.068 ( 4.15 %) |
|||
Open | High | Low | Volume | ||
$1.82 | $1.83 | $1.71 | 609076 | ||
Last updated 12.49pm 19/06/2025 ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RML
RESOLUTION MINERALS LTD
Craig Lindsay, In-Country CEO
Craig Lindsay
In-Country CEO
Previous Video
Next Video
SPONSORED BY The Market Online